Skip to content
Sign in
Venture capitalBacked 1 network startup

PharmStars Ventures

Boston fund investing only in PharmStars accelerator graduates: pharma-ready digital health, first 12 deals in rare-disease digital health.

Boston, United States
Ticket
—Not published
Assets under management
—
Founded
—
Stages
Pre-seedto Seed
Network startups backed
1
Co-investors
1most often with Sancus Capital

How they invest

Digital health startups that pharma companies can buy, license or deploy, with a 2025 emphasis on rare disease. The accelerator (10-week PharmaU) trains founders to sell into pharma, so pharma partnerships and regulatory credibility are the key filter.

Stage and ticket

Pre-seed and Seed; ticket not published. Investment is conditional on completing the PharmStars accelerator.

Geography

Global; cohorts are virtual, so geography matters less than pharma relevance.

What makes them say yes

  • Existing or plausible pharma customer/partner
  • Clinical or regulatory credibility (CE/FDA, validation studies)
  • Rare-disease or specialty-care angle

Red flags

  • No pharma go-to-market (pure consumer or provider play)
  • Not willing to join the accelerator

Sectors

  • HealthTech
  • Biotech & life sciences

Stages

  • Pre-seed
  • Seed

Geographies

  • Global

How to approach

Apply to the next PharmStars cohort; the fund only invests in graduates. Cromodata (graduate, $1.2M pre-seed) can give a founder reference on the programme.

Partners

  • Naomi Fried, PhDManaging Partner
  • Shrawan Patel, MDGeneral Partner

Portfolio

1 network startup · no other company

The one network investment, Cromodata (real-world clinical data marketplace), confirms the 'sell data or tools to pharma' pattern.

Gaps in the portfolio

  • Rare-disease patient engagement tools
  • Digital biomarkers
  • Women's health for pharma

Network startups

  • CromodataSWC 2026 Finalist

    Argentine marketplace turning de-identified records from a 47–84-facility Latin American network into research- and AI-ready clinical datasets.

    Argentina · HealthTech

    • Pre-seed (first round) · $1.2M · 1 Sept 2025LeadSource

Network startups that fit

4 analysed

CE-marked, ISO 13485 dermatology AI that supports diagnosis and scores severity from photos, partnering with NHS and Spanish health services.

CE-marked dermatology AI already partnering with Novartis and Almirall: textbook 'pharma-ready digital health'. It may be later-stage than typical cohorts (seed, $5.7M raised).

55%confidence

Evidence from the records

  • “partners listed such as NHS, SERMAS, SESPA, Sanitas, Adeslas, Novartis and Almirall”
  • “pharma-ready digital health startups”
Intro path
Cromodata founders (PharmStars graduate).
First step
Ask Legit.Health whether a PharmStars cohort fits its pharma pipeline plans.

Lisbon spin-off selling a contactless AI bedside lamp that detects night-time epileptic seizures and alerts caregivers.

Epileptic-seizure detection lamp on sale in the EU: a digital biomarker for a neurological condition that anti-epileptic drug makers could use in trials or patient support.

45%confidence

Evidence from the records

  • “Epileptic seizure detection”
  • “Lamp on sale in the EU”
First step
Propose a PharmStars application framed around pharma trial endpoints.

Smartphone eyelid-photo AI that screens for anemia in seconds without a blood draw, aimed at low-resource care.

Smartphone anemia-risk detection fits pharma use cases (iron therapies, oncology support). Pre-seed with an MIT Solve selection but no named pilot.

40%confidence

Evidence from the records

  • “AI anemia detection”
  • “MIT Solve 2024 selection (30/2,200)”
First step
Encourage Monere AI to apply with a pharma-partnership hypothesis.

Physician-founded Mallorca platform letting clinicians prescribe personalised lifestyle-medicine programmes, starting with menopause.

Clinical OS for lifestyle medicine (menopause) with a validated score; pharma fit is indirect (women's-health drug makers).

30%confidence

Evidence from the records

  • “FemTech / preventive and lifestyle medicine”
  • “score validated on 154 patients”
First step
Test pharma interest in iKi's menopause programme data before applying.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Sancus Capital

Sources